US 12,472,201 B2
Complexing agent salt formulations of pharmaceutical compounds
Jeffrey Becker, Santa Barbara, CA (US); Gregg Peterson, Santa Barbara, CA (US); and Jason Wallach, Philadelphia, PA (US)
Assigned to Bexson Biomedical, Inc., Santa Barbara, CA (US)
Filed by Bexson Biomedical, Inc., Santa Barbara, CA (US)
Filed on Nov. 4, 2022, as Appl. No. 17/981,348.
Application 17/981,348 is a continuation of application No. 17/546,880, filed on Dec. 9, 2021, granted, now 11,534,454.
Application 17/546,880 is a continuation of application No. PCT/US2021/059760, filed on Nov. 17, 2021.
Claims priority of provisional application 63/115,445, filed on Nov. 18, 2020.
Claims priority of provisional application 63/115,458, filed on Nov. 18, 2020.
Claims priority of provisional application 63/115,451, filed on Nov. 18, 2020.
Claims priority of provisional application 63/115,453, filed on Nov. 18, 2020.
Prior Publication US 2023/0124101 A1, Apr. 20, 2023
Int. Cl. A61K 31/724 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/724 (2013.01) [A61K 45/06 (2013.01)] 23 Claims
 
1. A pharmaceutical composition, comprising:
(i) a cationic pharmaceutical compound, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, comprising a protonated nitrogen atom,
wherein the cationic pharmaceutical compound is not ketamine; and
(ii) a substituted cyclodextrin comprising a plurality of anionic functional groups, wherein substantially all of the plurality of anionic functional groups of the substituted cyclodextrin are deprotonated, and at least one of the plurality of anionic functional groups acts as a counterion for the protonated nitrogen atom of the cationic pharmaceutical compound,
wherein a molar ratio of the cationic pharmaceutical compound to the substituted cyclodextrin is greater than 1:1, and
wherein the pharmaceutical composition comprising effective amounts of the cationic pharmaceutical compound and the substituted cyclodextrin has an osmolality, when in solution, that is at least about 10% less than a corresponding pharmaceutical composition prepared from a salt of the cationic pharmaceutical compound and a sodium salt of the substituted cyclodextrin.